This is a 90 day study, with patients receiving either oral Rosuvastatin or placebo for up to
28 days. The study will assess the affect of statins administered soon after burn injury on
C-reactive protein (CRP) levels, patient mortality and the incidence of septic shock. The
investigators also seek to describe the correlation between exposure to statins and
development of delirium and de-novo long-term cognitive impairment.
Hypothesis:
1. Statin administration within 96 hours of burn is safe, will decrease CRP, and will
decrease septic shock and mortality in burn patients.
2. The investigators hypothesize that burn patients will have a de-novo long term cognitive
impairment at 3 months after burn.
3. The investigators hypothesize the use of statins in burn patients will reduce the
development and the degree of cognitive impairment at 3 months post burn.